Pre-clinical studies have shown significant benefits can be derived from such a combinatorial strategy, suggesting that overcoming treatment resistance requires multifaceted and comprehensive interventions to counteract the tumor-promoting properties of IGF-1R. The gene discussed is IGF1R; the disease is neoplasm.